For US Healthcare Professionals Only

DORIBAX®: A distinct molecular structure

Meropenem structure
DORIBAX® structure

Strong binding at key targets

  • DORIBAX® demonstrated strong binding affinity to important penicillin-binding proteins in P aeruginosa (PBP 2 and PBP 3) in vitro*2

*In vitro activity does not necessarily correlate with clinical results; not intended to convey comparative safety or efficacy.

Please see Select Usage Information below.

References



 

Select Usage Information

 

  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting and modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy